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Abstract (247 words) 1 
 2 
Background: Established risk factors for pancreatic cancer include smoking, long-3 
standing diabetes, high body fatness, and chronic pancreatitis, all of which can be 4 
characterized by aspects of inflammatory processes. However, prospective studies 5 
investigating the relation between inflammatory markers and pancreatic cancer risk are 6 
scarce. 7 
Methods: We conducted a nested case-control study within the European Prospective 8 
Investigation into Cancer and Nutrition (EPIC), measuring pre-diagnostic blood levels 9 
of C-reactive protein (CRP), interleukin 6 (IL-6) and soluble receptors of tumour 10 
necrosis factor α (sTNF-R1, R2) in 455 pancreatic cancer cases and 455 matched 11 
controls. Odds ratios (OR) were estimated using conditional logistic regression models. 12 
Results: None of the inflammatory markers were significantly associated with risk of 13 
pancreatic cancer overall, although a borderline significant association was observed 14 
for higher circulating sTNF-R2 (crude OR = 1.52 [95% CI 0.97 – 2.39], highest vs. 15 
lowest quartile). In women, however, higher sTNF-R1 levels were significantly 16 
associated with risk of pancreatic cancer (crude OR = 1.97 [95% CI 1.02-3.79]). For 17 
sTNF-R2, risk associations seemed to be stronger for diabetic individuals and those 18 
with a higher BMI. 19 
Conclusion: Prospectively, CRP and IL-6 do not seem to play a role in our study with 20 
respect to risk of pancreatic cancer, whereas sTNF-R1 seemed to be a risk factor in 21 
women and sTNF-R2 might be a mediator in the risk relationship between overweight 22 
and diabetes with pancreatic cancer. Further large prospective studies are needed to 23 
clarify the role of pro-inflammatory proteins and cytokines in the pathogenesis of 24 
exocrine pancreatic cancer.. 25 
 26 
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Introduction 1 
Evidence is accumulating that systemic low-grade chronic inflammation in 2 
addition to local inflammation in the pancreas is involved in the pathogenesis of 3 
pancreatic cancer (Farrow & Evers, 2002; McKay et al, 2008; Whitcomb, 2004). 4 
Research findings pointing to this direction include the documented relationship of 5 
pancreatic cancer risk with chronic pancreatitis (Raimondi et al, 2010), as well as with 6 
smoking (Lynch et al, 2009; Vrieling et al, 2010), pre-existing and long-standing 7 
diabetes mellitus (Huxley et al, 2005), and excess weight (Genkinger et al, 2010), all of 8 
which are known or suggestive determinants of low-grade inflammatory states 9 
(Goncalves et al, 2011; Hotamisligil, 2006; Kolb & Mandrup-Poulsen, 2005; Whitcomb, 10 
2004). 11 
Even though the mechanisms by which chronic inflammation leads to 12 
carcinogenesis are not fully understood, it is generally accepted that inflammation 13 
results in repeated DNA damage and in the accumulation of genetic defects (McKay et 14 
al, 2008). However, pro-inflammatory cytokines and growth factors are also released in 15 
response to the tumour, making it difficult to distinguish between cause and effect in 16 
the inflammatory processes (McKay et al, 2008). 17 
Circulating C-reactive protein (CRP) concentration, an acute-phase protein 18 
produced in the liver, is increased in pancreatic cancer patients (Barber et al, 1999; 19 
Moses et al, 2009; Mroczko et al, 2010), most likely as part of the systemic 20 
inflammatory response to the tumour. Interleukin-6 (IL-6) and tumour necrosis factor 21 
alpha (TNF-α) are up-regulating factors of CRP and have also been shown to be 22 
increased in pancreatic cancer patients (Barber et al, 1999; Ebrahimi et al, 2004; 23 
Moses et al, 2009; Mroczko et al, 2010; Talar-Wojnarowska et al, 2009). Prospectively, 24 
increased levels of CRP have inconsistently been associated with pancreatic cancer 25 
risk. To our knowledge, prospective studies on the association of IL-6, TNF-α, or its 26 
receptors with risk of pancreatic cancer are lacking. 27 
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We measured prediagnostic concentrations of CRP, IL-6, and soluble TNF receptors 1 
(sTNF-R1 and R2) in blood samples of 455 primary exocrine pancreatic cancer cases 2 
and 455 individually matched controls within the Prospective Investigation into Cancer 3 
and Nutrition (EPIC) as possible reflections of either pancreatic cancer or a metabolic 4 
risk factor potentially increasing pancreatic cancer risk by aggravating pancreatic 5 
inflammatory disease. 6 
 7 
Materials and Methods 8 
Study Population 9 
The European Prospective Investigation into Cancer and Nutrition (EPIC) is a 10 
large cohort study conducted in 23 centres in ten European countries (Denmark, 11 
France, Germany, Greece, Italy, the Netherlands, Spain, Sweden, and the United 12 
Kingdom). Detailed descriptions of study design, population, and baseline data 13 
collection of the cohort can be found elsewhere (Haftenberger et al, 2002; Riboli et al, 14 
2002). Briefly, about 370 000 women and 150 000 men were enrolled between 1992 15 
and 2000. Participants provided information on dietary habits and lifestyle factors, and 16 
in addition, weight, height, and waist and hip circumferences were measured at 17 
baseline. Each participant provided informed consent, and the local ethical review 18 
committees approved the EPIC cohort study as well as the current project. 19 
 20 
Blood Sample Collection and Storage 21 
In the seven EPIC core countries (France, Germany, Greece, Italy, the 22 
Netherlands, Spain, and the United Kingdom), blood samples were collected at 23 
baseline, based on a standardized protocol and aliquoted in plastic straws (plasma, 24 
serum, erythrocytes, and buffy coat for DNA). The aliquoted specimens were then 25 
stored in a central biorepository in liquid nitrogen (-196°C). In Sweden, all samples 26 
were stored locally in freezers at -70°C and in Denmark in nitrogen vapour (-150°C). In 27 
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the present study, Norway was excluded because blood samples were only recently 1 
collected and very few pancreatic cancer cases have been diagnosed after blood 2 
donation. 3 
 4 
Follow-up for Cancer Incidence and Vital Status 5 
In six of the participating countries (Denmark, Italy, the Netherlands, Spain, 6 
Sweden, and the United Kingdom), follow-up of cancer cases was based on population 7 
registries. In the other three countries (France, Germany, and Greece), a combination 8 
of methods was used including health insurance records, cancer and pathology 9 
registries, and active follow-up through study subjects and their next-of-kin. In all EPIC 10 
centres, data on vital status is collected from mortality registries at the regional or 11 
national level, which is combined with health insurance data (France) or data collected 12 
by active follow-up (Greece). Cases reported in this study were all diagnosed up to the 13 
latest dates of complete follow-up, which was between December 2002 and 2005, 14 
depending on the study centre. For Germany, Greece, and France, the end of follow-up 15 
was the last known contact, date of diagnosis, or date of death, whichever came first. 16 
 17 
Selection of Case and Control Subjects 18 
Up to December 2006, follow-up has led to the identification of 578 incident 19 
cases of non-endocrine pancreas cancer that were coded according to ICD-10 (C25.0-20 
25.3, 25.7-25.9), and for 455 of these cases blood specimens were available. 21 
Exclusion criteria were occurrence of other malignant tumours preceding the diagnosis 22 
of pancreatic cancer, except for non-melanoma skin cancer. Of the 455 cases, 334 23 
(76%) were microscopically confirmed and the remaining 24% were diagnosed by 24 
imaging results, physical examination, or clinical symptoms. Most tumours occurred in 25 
the head of the pancreas (42%), followed by body (7%) and tail (5%), while the rest of 26 
the tumours were of unknown localization. For each case, one control subject was 27 
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selected, that was alive and free of cancer at the time the index case was diagnosed, 1 
using an incidence density sampling procedure. All identified cases were matched with 2 
one control by centre, sex, age at blood collection (+/- 3 years), date of blood donation 3 
(+/- 3 months), time of blood donation (+/- 2 hours), fasting status (<3 hours, 3-6 hours, 4 
>6 hours after last meal) and use of hormones (oral contraceptive pill, hormone or 5 
oestrogen replacement therapy). 6 
 7 
Laboratory Assays 8 
Plasma (in Scandinavian samples) and serum concentrations of CRP were 9 
measured by multiplex immunoassays using the Fluorokine MAP Obesity Base Kit 10 
(R&D Systems, Inc., Minneapolis, MN, USA). IL-6 and sTNF receptors were measured 11 
by enzyme linked immune sorbent assays (ELISA) using the Quantikine kit (R&D 12 
Systems, Inc., Minneapolis, MN, USA). The total amount of free receptor plus the total 13 
amount of receptor bound to TNF is measured with this method. All measurements 14 
were performed in our specialized immunoassay laboratory of the Division of Cancer 15 
Epidemiology (German Cancer Research Center, Heidelberg, Germany). Samples of 16 
cases and matched controls were analyzed within the same analytical batch. Intra-17 
batch and inter-batch coefficients of variation were 6.6 and 10.8% for IL-6, 3.6 and 18 
4.1% for sTNF-R1, 5.5 and 11.0% for sTNF-R2, and 10.3 and 11.6% for CRP. Units of 19 
IL-6 are expressed as pg/mL, of sTNF receptors as ng/mL, and of CRP as mg/L. One 20 
batch during the sTNF-R2 measurements did not perform well and, therefore, 70 21 
subjects were excluded due to technically invalid results (all from Malmo, Sweden). 22 
 23 
Statistical Analysis 24 
Case and control differences across baseline characteristics were assessed by 25 
paired t-tests (continuous variables) or by generalized McNemar’s Test (categorical 26 
variables). Spearman’s partial rank correlation coefficients [r] adjusted for age, sex, and 27 
10 
 
EPIC recruitment centre were used to assess the strength of associations between 1 
waist circumference, waist-hip-ratio, BMI, glycated haemoglobin (HbA1c), and 2 
inflammatory markers, as well as for the correlation between the inflammatory markers. 3 
Odds ratios (OR) and corresponding 95% confidence intervals (CI) for pancreatic 4 
cancer at different serum levels of IL-6, sTNF receptors, and CRP were calculated by 5 
conditional logistic regression models, using the exposure assessments of the matched 6 
case-control sets. Continuous measurements of the inflammatory markers were log2 7 
transformed to achieve approximate normality. In this scale, a unit increase 8 
corresponds to a doubling of concentration. Quartile cut-points were based on the 9 
distribution of biomarkers among controls. Sex-specific quartile cut-points had a 10 
negligible effect on risk estimates and were, therefore, not applied. Modelling the 11 
median within each quartile as a continuous variable was used to assess linear trends 12 
in ORs. Testing the model fit for categorical vs. continuous models resulted in very 13 
similar AICs, with a slightly better fit for the latter model. 14 
Inflammatory markers may be downstream in the causal chain of excess body 15 
weight, smoking, or diabetes and pancreatic cancer. Alternatively, other pathways 16 
might explain associations of these conditions with risk of pancreatic cancer and, 17 
hence, inflammatory markers may be independently related to cancer or not at all. We 18 
tried to elucidate these rather complex and yet unknown relationships in our study by 19 
applying different adjustment models and by performing several subgroups analyses. 20 
All these models and methods are of exploratory nature in our study. 21 
Potential confounding of factors other than those controlled for by matching were 22 
examined by assessing the association of these factors with pancreatic cancer risk 23 
using unconditional logistic regression models adjusted for matching factors, by 24 
correlation analyses, and by including these as additional factors in conditional logistic 25 
regression models. BMI, waist-hip-ratio, waist circumference, alcohol consumption, 26 
current and past tobacco smoking, and diabetes were considered as potential 27 
11 
 
confounders. Variables remained in the models, if they were associated with pancreatic 1 
cancer, correlated with the inflammatory markers, or changed the β estimate by more 2 
than 10%. Based on these conditions, BMI as a continuous variable and smoking as a 3 
categorical variable [never smoking, former smoking (quitting smoking < 10 years ago, 4 
≥ 10 years ago), current smoking (< 10, 10 - 20, ≥ 10 cigarettes a day), missing] were 5 
considered as confounding factors and remained in the multivariate adjusted model. To 6 
assess a possible confounding effect of diabetes on the risk associations, we controlled 7 
for diabetes in further exploratory analyses. Subjects were defined as diabetics if they 8 
self-reported the condition in the baseline questionnaire at recruitment (n=52) and/or 9 
had glycated haemoglobin (HbA1c) levels ≥ 6.5% in the current study (n=93). This 10 
percentage is used as a cut-off for diabetes diagnosis (ADA, 2009). HbA1c has been 11 
measured previously in the same study population (Grote et al, 2011). Physical activity 12 
and socio-economic status did not markedly change the risk estimates and were, 13 
therefore, not included in the final model. 14 
Subgroup analyses were performed to assess possible effect modifications by 15 
sex, diabetes and smoking status, by median age (62 years), waist circumference 16 
(96cm for men, 80 for women), waist-hip-ratio (0.95 for men, 0.80 for women), and 17 
median BMI (26.2 kg/m2 for men, 24.6 for women), or by lag-time (time between blood 18 
collection and diagnosis of pancreatic cancer, ≤ vs. > 5 years). Cross-product terms 19 
were added in logistic regression models and Wald tests were performed to examine 20 
whether any apparent heterogeneity of effect was significant. To limit reverse causation 21 
bias which could occur when the advanced tumour causes changes in inflammatory 22 
marker levels, we performed subgroup analyses with two years of follow-up as a cut-23 
point (≤ vs. > 2 years). 24 
All statistical analyses were conducted using the Statistical Analysis System 25 
(SAS) software package, Version 9.2 (SAS Institute Inc., Cary, North Carolina, USA). 26 
All statistical tests were two-tailed and significant at the 5%-level. 27 
12 
 
 1 
Results 2 
Baseline characteristics of pancreatic cancer cases and matched control subjects 3 
are shown in Table 1. Mean age at recruitment into the initial cohort was 58 years and 4 
mean age of cases at pancreatic cancer diagnosis was 63 years, resulting in mean 5 
follow-up time of 5.3 years for cases (range 0-13). Female pancreatic cancer cases 6 
had a significantly higher BMI and waist-circumference than corresponding controls, 7 
but no difference in waist-hip-ratio was observed. For men, however, no significant 8 
difference for any of the anthropometric measures comparing cases and controls was 9 
seen. A higher percentage of cases currently smoked compared to controls (31 vs. 10 
22%). At baseline, cases also reported more often to be diabetic and/or had HbA1c 11 
levels ≥ 6.5% compared with controls (14 vs. 8%). However, these results are not 12 
mutually adjusted and serve descriptive purposes only. 13 
Among controls, sTNF-R1 and sTNF-R2 showed a high degree of correlation. 14 
The correlation of circulating CRP levels with IL-6, sTNF-R1, and sTNF-R2 15 
concentrations was relatively high with Spearman’s rank correlation coefficients up to 16 
0.44. BMI, waist circumference, and waist-hip-ratio correlated moderately with CRP 17 
and IL-6 and to lesser extent with sTNF-R1 but not with sTNF-R2 concentrations 18 
(Table 2). Participants with diabetes (self-reported at baseline and/or HbA1c ≥ 6.5%) 19 
and those who smoked had higher levels of CRP and IL-6 than non-diabetics (Table 2). 20 
Mutual adjustments for smoking categories and/or BMI resulted in unaltered (diabetes) 21 
or stronger associations (smoking, data not shown).  22 
The potential confounders or effect modifiers overweight (OR = 1.05 [95% CI 23 
1.01-1.08], per 5 BMI units), smoking (OR = 1.84 [95% CI 1.30-2.60], current vs. 24 
never), and diabetes (OR = 1.74 [95% CI 1.12-2.71]) were associated with risk of 25 
pancreatic cancer in our study. 26 
 27 
13 
 
Pancreatic cancer risk tended to be increased with higher levels of sTNF-R2 1 
(crude OR = 1.52 [95% CI 0.97 – 2.39] comparing highest with lowest quartiles, p-trend 2 
over quartiles = 0.07); but these associations were not significant at the 5%-level, and 3 
BMI and smoking adjustments attenuated the risks of pancreatic cancer (Table 3). 4 
Elevated CRP (crude OR = 1.36 [95% CI 0.92 – 2.01], p-trend = 0.26), IL-6 (OR = 1.30 5 
[95% CI 0.84 – 2.00], p-trend = 0.61), and sTNF-R1 levels (OR = 1.23 [95% CI 0.78-6 
1.94], p-trend = 0.23) showed no significant association with risk of pancreatic cancer. 7 
Adjustments for HbA1c levels and mutually for the other inflammatory markers in 8 
addition to BMI and smoking categories attenuated risk estimates for elevated levels of 9 
inflammatory markers closer to 1.0 (data not shown). Exclusion of subjects with CRP 10 
levels above 10 mg/L (as this is more likely an indication for an acute rather than a 11 
chronic inflammatory state) had no effect on the association between CRP levels and 12 
pancreatic cancer risk (data not shown). Women tended to be at increased pancreatic 13 
cancer risks for higher CRP or sTNF receptor levels, and specifically so for sTNF-R1, 14 
although risk estimates were inconsistently significant between categorical and 15 
continuous analyses and between crude and BMI and smoking adjusted models (Table 16 
3). 17 
 18 
Tests for heterogeneity of continuous sTNF receptors, adjusted for matching 19 
factors, resulted in statistically significant differences in pancreatic cancer risk by 20 
median BMI, diabetes and smoking status, but not by median waist circumference, 21 
waist-hip-ratio or median age. Compared to never smokers, risks in former and current 22 
smokers were elevated albeit not statistical significant. Diabetics (p interaction = 0.001) 23 
and subjects with a BMI above the median (p interaction = 0.04) had a significantly 24 
higher risk of pancreatic cancer with elevated levels of sTNF-R2 than non-diabetics or 25 
subjects with lower than median BMI, respectively (Figure 1b). Adjusting subgroup 26 
analyses for BMI, smoking categories, HbA1c levels, and/or mutually for inflammatory 27 
14 
 
markers attenuated the risk estimates to non-significance (data not shown). 1 
Interestingly, higher circulating CRP and IL-6 levels tended to be related to increased 2 
pancreatic cancer risk in leaner subjects, although ORs and tests for interaction were 3 
not statistically significant (Figures 1c/d). 4 
 5 
Discussion 6 
In our nested case-control study of 455 pancreatic cancer subjects and 455 7 
individually matched controls higher circulating levels of sTNF-R2, but not of sTNF-R1, 8 
CRP, and IL-6 levels tended to be positively associated with the risk of pancreatic 9 
cancer. Stratification by sex revealed significantly increased pancreatic cancer risks in 10 
women for higher sTNF-R1 levels. Positive associations between sTNF-R2 and 11 
pancreatic cancer seemed to be likely for diabetic subjects, those with a higher BMI, 12 
and possibly also for smokers. 13 
 14 
In the acute-phase response to tissues damage, infection, inflammation, or 15 
malignant neoplasia, CRP is increasingly produced by hepatocytes, predominantly 16 
under control by IL-6. CRP binds to damaged cell membranes or apoptotic cells, 17 
forming an aggregate that activates the complement pathway, resulting in the 18 
phagocytosis of the damaged cells and in increased pro-inflammatory 19 
pathophysiological effects. CRP, therefore, reflects ongoing inflammation and/or tissue 20 
damage and functions as a pro-inflammatory mediator. In this context, it may not only 21 
be a marker of a disease, but it may also contribute to pathogenesis (Pepys & 22 
Hirschfield, 2003). In several small hospital-based case-control studies, CRP levels 23 
were significantly higher in pancreatic cancer cases compared to chronic pancreatitis 24 
patients or controls (Barber et al, 1999; Moses et al, 2009; Mroczko et al, 2010). In 25 
addition, elevated levels of CRP were associated with a poor prognosis in pancreatic 26 
cancer patients (McKay et al, 2008). Prospectively, no association was observed in a 27 
15 
 
Greek study with 14 pancreatic cancer cases (Trichopoulos et al, 2006), whereas a 1 
weak decrease in pancreatic cancer risk with an OR of 0.94 [95% CI 0.89-0.99] was 2 
seen among 311 cases in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention 3 
Study (ATBC) cohort of male Finish smokers (Douglas et al, 2010). The same authors 4 
did not find an association in the Ovarian Cancer Screening Trial (PLCO) or in 5 
combined analyses of both cohorts. Our results are in line with the prospective Greek 6 
and PLCO study showing no association of CRP with risk of pancreatic cancer. 7 
 8 
No prospective study has been conducted so far to assess the association of 9 
circulating TNF-α, its soluble receptors, or IL-6 levels with risk of pancreatic cancer, 10 
both up-regulators of CRP. TNF-α is a pro-inflammatory cytokine produced by many 11 
cell types, including cancer cells, upon exogenous noxious stimuli. The effects of TNF- 12 
α are mediated mainly by two receptors, TNF-R1 and TNF-R2, which also circulate in 13 
soluble forms upon shedding. TNF receptor activation leads to induction of genes 14 
involved in inflammation and cell survival, resulting in the activation of nuclear factor-κB 15 
(NF-κB). However, if NF-κB activation is inadequate, apoptosis is mediated via 16 
accumulation of reactive oxygen species as a late response to TNF-α. This cytokine, 17 
thus, is not only involved in maintenance of the immune system, but also in 18 
pathological processes such as malignant diseases. The majority of cell types and 19 
tissues express both receptor types (Balkwill, 2006) and among colon cancer patients it 20 
has been shown that the concentrations of sTNF-Rs correlate with the stage of disease 21 
as tumour cells have a greater tendency than non-malignant cells to shed forms of their 22 
cell surface proteins (Aderka, 1996). Soluble TNF receptors can serve as TNF 23 
antagonists, carrier proteins of TNF, slow release reservoirs for TNF, and stabilizers of 24 
TNF-bioactivity. It is not known, however, whether the two soluble receptors have 25 
distinct or similar functions (Aderka, 1996), and based on this, we cannot explain, why 26 
we observed a potential increase in pancreatic cancer risk for elevated sTNF-R2 but 27 
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not for sTNF-R1. It might be, however, that sTNF-R2 plays a more prominent role in 1 
pancreatic cancer development. This aspect needs to be explored in functional studies. 2 
So far, TNF-α and/or the soluble receptors have been assessed in hospital-based 3 
case-control studies with pancreatic cancer patients, observing either higher levels of 4 
TNF-α/soluble TNF receptors among pancreatic cancer subjects than among controls 5 
(healthy volunteers or chronic pancreatitis patients (Barber et al, 1999; Talar-6 
Wojnarowska et al, 2009)), or no difference in serum levels (Ebrahimi et al, 2004). To 7 
our knowledge, our nested-case control study within the prospective EPIC cohort study 8 
is the first to address the association of sTNF receptors with risk of pancreatic cancer, 9 
and we observed a non-significant increase in risk overall, which was more apparent 10 
for sTNF-R2 than sTNF-R1, and which was attenuated after adjustments for smoking 11 
status, BMI, and HbA1c levels or diabetes status. It is unclear why we found a 12 
difference in risk between men and women with elevated risks for increasing levels of 13 
sTNF-R1 in women only. 14 
 15 
As with TNF-α, pancreatic cancer patients’ IL-6 concentrations have shown to be 16 
higher than in healthy controls in hospital-based case-control studies (Barber et al, 17 
1999; Ebrahimi et al, 2004; Moses et al, 2009; Mroczko et al, 2010). In contrast to 18 
these observations, in our prospective study we did not find elevated pre-diagnostic IL-19 
6 concentrations in subjects who became pancreatic cancer cases later in time 20 
compared to non-cancer controls at baseline. IL-6 is synthesized by many cell types in 21 
response to stimulation from TNF-α and IL-1 and indirectly regulates cell proliferation 22 
and apoptosis through its activation of other factors. Therefore, IL-6 plays a role in 23 
chronic inflammation, which may enhance cancer development (Hodge et al, 2005). 24 
However, due to the small number of prospective studies so far investigating the 25 
relationship of IL-6 with cancer, a recent published review concluded that it is yet 26 
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impossible to determine whether IL-6 is causally related to cancer (Heikkilä et al, 1 
2008). 2 
 3 
It has been shown in a wide range of studies that CRP, IL-6, TNF-α, and TNF 4 
receptor levels vary by body weight, with higher levels among overweight or obese 5 
compared to normal weight subjects, and with decreasing levels during weight loss 6 
(Forsythe et al, 2008; Himmerich et al, 2006). Furthermore, compared with never 7 
smokers, cigarette smokers also have significantly higher levels of CRP and IL-6, and 8 
possibly also of TNF receptors (Fernandez-Real et al, 2003). Finally, subclinical 9 
systemic inflammation has been reported in type 2 diabetes (Kolb & Mandrup-Poulsen, 10 
2005), including elevated levels of the aforementioned and evaluated parameters in our 11 
study. In our study, elevated levels of CRP, IL-6 and sTNF-R1 correlated with excess 12 
weight and, in addition, higher CRP and IL-6 levels were associated with smoking and 13 
diabetes.  14 
Furthermore, overweight, smoking, or diabetic participants at baseline were at 15 
increased pancreatic cancer risk. This risk was even stronger if overweight or diabetic 16 
participants had elevated levels of sTNF-R2, even though this marker was not 17 
correlated with BMI or associated with diabetes in controls. This can be interpreted as 18 
sTNF-R2 being a mediator of the relationship between overweight and/or diabetes and 19 
pancreatic cancer. A similar scenario is likely for sTNF-R1, but our results do not 20 
clearly support this hypothesis (Figure 1a). In contrast, stratification by median BMI, 21 
diabetes or smoking status resulted in similar weak risk estimates for elevated CRP 22 
and IL-6 concentrations. It seems as if, regardless of the presence of a putative 23 
pancreatic cancer risk factor (overweight, diabetes, and smoking), these inflammatory 24 
markers are not associated with pancreatic cancer risk themselves. In addition, they 25 
also do not appear to be in the causal chain between risk factor and cancer. 26 
18 
 
Some strengths and limitations of our study should be mentioned. Although a 1 
single measurement of a biomarker, as assessed in our study, could result in random 2 
misclassification, CRP, IL-6, and sTNF receptors have been shown to be reliably 3 
measured over time (Clendenen et al, 2010; Gu et al, 2009). A major strength of our 4 
study is that questionnaire data and blood samples were collected prospectively 5 
around the same time point, prior to pancreatic cancer diagnosis, which reduces the 6 
possibility of reverse causation bias to some extent. In addition, pancreatic cancer risk 7 
seemed to be stronger for elevated sTNF receptor levels among subjects with longer 8 
follow-up times. A limitation of our study is that information on pancreatic or liver 9 
disorders, on inflammatory diseases, or on use of anti-inflammatory drugs was not 10 
recorded for most of the EPIC centres; therefore, controlling for these potential 11 
confounders was not possible. Consequently, we cannot exclude the possibility that the 12 
observed suggestive increased pancreatic cancer risk among individuals with elevated 13 
sTNF-R2 levels may partly be due to chronic pancreatitis or impaired liver function, for 14 
example. Furthermore, number of subjects in specific subgroups were rather small, 15 
thus, we cannot rule out that results obtained from these analyses are chance findings. 16 
Further large prospective studies are needed to verify our results in the respective 17 
subgroups with sufficient power to detect significant risk associations. 18 
 19 
Conclusion 20 
Prospectively, CRP and IL-6 do so seem to play a role in our study with respect 21 
to risk of pancreatic cancer, whereas sTNF-R1 seemed to be a risk factor in women 22 
and sTNF-R2 might be a mediator in the risk relationship between overweight and 23 
diabetes with pancreatic cancer. In order to clarify the role of pro-inflammatory proteins 24 
and cytokines in the pathogenesis of exocrine pancreatic cancer, more prospective 25 
studies in large settings are needed, controlling for the potential bias of other conditions 26 
and stratifying by sex. 27 
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1c) CRP 
Subgroup Ca / Co OR (95% CI) P int a 
    
All 449 / 449 1.08 (0.99-1.18)  
    
BMI < median b 200 / 226 1.13 (1.00-1.28) 0.3 
BMI ≥ median 250 / 226 1.01 (0.89-1.15)  
    
Non-diabetics 373 / 401 1.05 (0.95-1.15) 0.1 
Diabetics c 59 / 34 1.17 (0.85-1.63)  
    
Never smoker 161 / 197 1.08 (0.94-1.23) 0.9 
Former smoker 143 / 149 1.09 (0.93-1.29)  
Current smoker 141 / 101 1.04 (0.88-1.23)  
    
FUP ≤ 2yrs d 77 / 77 1.10 (0.90-1.35) 0.9 
FUP > 2yrs 373 / 375 1.08 (0.98-1.18)  
1d) IL-6 
Subgroup Ca / Co OR (95% CI) P int a 
    
All 424 / 424 1.09 (0.95-1.26)  
    
BMI < median b 193 / 216 1.19 (1.00-1.42) 0.4 
BMI ≥ median 247 / 221 0.93 (0.76-1.13)  
    
Non-diabetics 364 / 388 1.06 (0.93-1.22) 0.02 
Diabetics c 59 / 33 1.18 (0.71-1.96)  
    
Never smoker 155 / 193 1.03 (0.84-1.26) 0.2 
Former smoker 144 / 142 1.16 (0.93-1.45)  
Current smoker 136 / 97 0.99 (0.77-1.28)  
    
FUP ≤ 2yrs d 74 / 74 1.09 (0.75-1.58) 0.9 
FUP > 2yrs 366 / 363 1.09 (0.94-1.28)  
1 2 3 4 5
1 2 3 4 5
 
 
 
 
 
 
 
1a) sTNF-R1 
Subgroup Ca / Co OR (95% CI) P int a 
    
All 390 / 390 1.39 (0.87-2.23)  
    
BMI < median b 191 / 209 1.14 (0.60-2.18) 0.3 
BMI ≥ median 236 / 203 1.19 (0.68-2.08)  
    
Non-diabetics 354 / 366 1.08 (0.68-1.70) 0.003 
Diabetics c 56 / 30 3.09 (0.84-11.36)  
    
Never smoker 155 / 184 1.07 (0.55-2.11) 0.05 
Former smoker 133 / 131 1.10 (0.52-2.34)  
Current smoker 134 / 92 1.20 (0.54-2.68)  
    
FUP ≤ 2yrs d 73 / 69 0.81 (0.26-2.55) 0.3 
FUP > 2yrs 354 / 343 1.55 (0.92-2.62)  
1b) sTNF-R2 
Subgroup Ca / Co OR (95% CI) P int a 
    
All 414 / 414 1.55 (0.99-2.44)  
    
BMI < median b 179 / 204 0.89 (0.50-1.58) 0.04 
BMI ≥ median 238 / 213 1.93 (1.11-3.37)  
    
Non-diabetics 349 / 375 1.12 (0.73-1.72) 0.001 
Diabetics c 54 / 29 4.76 (1.11-20.37)  
    
Never smoker 148 / 187 0.92 (0.47-1.81) 0.001 
Former smoker 133 / 136 1.40 (0.69-2.84)  
Current smoker 131 / 89 1.61 (0.77-3.37)  
    
FUP ≤ 2yrs d 73 / 73 0.97 (0.34-2.80) 0.3 
FUP > 2yrs 344 / 344 1.72 (1.05-2.84)  
Table 1. Baseline characteristics of pancreatic cancer cases and matched controls 
Variable Cases (n=455) Controls (n=455)  p-valuea 
    
Women, n (%) 235 (52) 235 (52) matched 
Age at recruitment [y], mean (range) 58 (30 – 76) 58 (30 – 76) matched 
Age at diagnosis [y], mean (range) 63 (37 – 82) -  
Follow-up [y], mean (range) 5.3 (0 – 13) -  
    
BMI [kg/m2], mean ± SD    
     Male 26.8 ± 3.6 26.7 ± 3.7 0.7 
     Female 26.5 ± 5.0 25.2 ± 4.3 0.002 
Waist-hip ratio, mean ± SD    
     Male 0.95 ± 0.06 0.95 ± 0.06 0.6 
     Female 0.82 ± 0.07 0.81 ± 0.06 0.09 
Waist circumference [cm], mean ± SD    
     Male 96.3± 9.9 96.7 ± 10.2 0.7 
     Female 84.4 ± 12.5 81.2 ± 10.7 0.001 
    
Smoking status, n (%)   < 0.001 
     Never 162 (36) 198 (44)  
     Former 145 (32) 151 (33)  
     Current 143 (31) 101 (22)  
     Unknown 5 (1) 5 (1)  
    
Alcohol intake at recruitment [g/d], mean ± SD   0.9 
     Male 21 ± 26 23 ± 31  
     Female 9 ± 13 8 ± 11  
    
Fasting status, n (%)   matched 
     Fasting (≥ 6 hours) 118 (26) 113 (25)  
     In between (3 - 6 hours) 78 (17) 78 (17)  
     Non fasting (< 3 hours) 177 (39) 183 (40)  
     Unknown 82 (18) 81 (18)  
 
Diabetes status, n (%)    
     Self-reported diabetes at recruitment 33 (8) 19 (4) 0.05 
     Subjects HbA1c ≥ 6.5% 54 (12) 29 (6) 0.006 
     Self-reported diabetes or HbA1c ≥ 6.5% 59 (14) 34 (8) 0.01 
     Unknown 18 (4) 17 (4)  
    
CRP [mg/L], geometric mean (95% CI)    
     Men 1.12 (0.97-1.29) 1.08 (0.94-1.25) 0.8 
     Women 1.24 (1.08-1.42) 0.97 (0.84-1.12) 0.02 
IL-6 [pg/mL], geometric mean (95% CI)    
     Men 1.79 (1.63-1.96) 1.69 (1.52-1.89) 0.6 
     Women 1.58 (1.43-1.74) 1.44 (1.31-1.59) 0.3 
sTNF-R1 [ng/mL], geometric mean (95% CI)    
     Men 1.33 (1.28-1.37) 1.36 (1.32-1.41) 0.3 
     Women 1.39 (1.34-1.44) 1.32 (1.28-1.36) 0.003 
sTNF-R2 [ng/mL], geometric mean (95% CI)    
     Men 2.31 (2.23-2.40) 2.28 (2.20-2.37) 0.5 
     Women 2.43 (2.35-2.51) 2.33 (2.26-2.40) 0.04 
    
 
a P values for continuous variables were based on paired t tests; p values for categorical variables 
were based on generalized McNemar’s tests 
SD = standard deviation, CI = confidence interval 
Note: matching factors were EPIC recruitment centre, sex, age at blood collection, date of blood 
donation, time of blood donation, fasting status, and use of hormones (in women) 
 
Table 2: Correlation (95% CI) between inflammatory markers and selected covariates in 
control participants a 
Covariate CRP IL-6 sTNF-R1 sTNF-R2 
     
IL-6 0.44 (0.35 to 0.53)    
sTNF-R1 0.29 (0.18 to 0.39) 0.33 (0.22 to 0.42)   
sTNF-R2 0.27 (0.16 to 0.37) 0.23 (0.12 to 0.33) 0.65 (0.58 to 0.71)  
BMI 0.40 (0.30 to 0.49) 0.29 (0.18 to 0.39) 0.17 (0.06 to 0.28) 0.05 (-0.06 to 0.16) 
Waist 0.32 (0.22 to 0.42) 0.31 (0.20 to 0.41) 0.21 (0.10 to 0.31) 0.10 (-0.01 to 0.21) 
WHR 0.23 (0.13 to 0.34) 0.25 (0.14 to 0.35) 0.16 (0.04 to 0.26) 0.09 (-0.03 to 0.20) 
HbA1c 0.16 (0.05 to 0.27) 0.09 (-0.02 to 0.20) 0.10 (-0.01 to 0.21) 0.01 (-0.10 to 0.12) 
Diabetes b 1.37 (1.08 - 1.74) 1.49 (1.06 - 2.11) 1.41 (0.44 - 4.55) 1.30 (0.42 - 4.02) 
Smoking c 1.30 (1.10 - 1.54) 1.36 (1.06 - 1.74) 1.60 (0.72 - 3.58) 0.97 (0.43 - 2.16) 
Sex d 1.07 (0.95 - 1.21) 1.21 (1.02 - 1.44) 1.79 (0.97 - 3.31) 0.90 (0.50 - 1.62) 
Age e 0.13 (0.03 to 0.23) 0.18 (0.08 to 0.28) 0.30 (0.20 to 0.39) 0.32 (0.22 to 0.41) 
     
 
CRP denotes C-reactive protein, IL-6 interleukin 6, sTNF-R1 and sTNF-R2 soluble tumour necrosis 
factor receptor 1 and 2, BMI body mass index, waist waist circumference, WHR waist-to-hip ratio, 
HbA1c glycated haemoglobin, age age at recruitment. 
a For continuous covariates Spearman’s partial rank correlation coefficients were applied. For 
categorical covariates we used logistic regression. Both methods were performed in controls and 
adjusted for age, sex and EPIC recruitment centre if not stated otherwise. 
b Diabetic (HbA1c ≥ 6.5% or self-reported diabetes at baseline) vs. non-diabetic participants 
c Current vs. never smokers 
d Men vs. women, adjusted for age and EPIC recruitment centre. 
e Adjusted for sex and EPIC recruitment centre. 
 
Table 3. Risk [OR (95% CI)] of pancreatic cancer by quartiles of CRP, IL-6, and sTNF receptors, all subjects combined and stratified by sex a 
  Quartiles b  OR for doubling 
  1 2 3 4 Ρ trend c in concentration 
        
CRP Quartile cut-offs [mg/L] 0.02 - 0.51 0.52 - 1.04 1.05 - 2.05 2.06 - 34.07   
 No. cases / controls (total 449 / 449) 88 / 112 112 / 112 130 / 113 119 / 112   
 Crude d 1.0 1.30 (0.88-1.94) 1.45 (1.00-2.10) 1.36 (0.92-2.01) 0.3 1.08 (0.99-1.18) 
 Adjusted for smoking, BMI 1.0 1.25 (0.83-1.88) 1.20 (0.80-1.79) 1.02 (0.66-1.57) 0.6 1.01 (0.92-1.11) 
 Men, crude 1.0 1.38 (0.76-2.52) 0.98 (0.56-1.70) 1.23 (0.68-2.21) 0.9 1.02 (0.90-1.15) 
 Adjusted for smoking, BMI 1.0 1.39 (0.75-2.58) 0.93 (0.52-1.66) 1.09 (0.58-2.04) 0.7 1.00 (0.88-1.13) 
 Women, crude 1.0 1.15 (0.67-1.97) 2.14 (1.27-3.59) 1.44 (0.85-2.47) 0.1 1.16 (1.02-1.31) 
 Adjusted for smoking, BMI 1.0 1.19 (0.67-2.11) 1.65 (0.92-2.98) 0.99 (0.54-1.81) 0.6 1.02 (0.89-1.18) 
        
IL-6 Quartile cut-offs [pg/ml] 0.16 - 0.94 0.95 - 1.57 1.58 - 2.65 2.66 - 9.66   
 No. cases / controls (total 424 / 424) 86 / 106 123 / 106 108 / 107 107 / 105   
 Crude d 1.0 1.45 (0.98-2.15) 1.28 (0.85-1.93) 1.30 (0.84-2.00) 0.6 1.09 (0.95-1.26) 
 Adjusted for smoking, BMI 1.0 1.29 (0.86-1.94) 0.97 (0.62-1.51) 1.01 (0.64-1.61) 0.7 0.99 (0.85-1.16) 
 Men, crude 1.0 2.02 (1.11-3.68) 1.73 (0.92-3.26) 1.36 (0.70-2.64) 0.9 1.07 (0.86-1.32) 
 Adjusted for smoking, BMI 1.0 1.88 (1.00-3.51) 1.51 (0.75-3.04) 1.21 (0.60-2.45) 0.6 1.00 (0.80-1.25) 
 Women, crude 1.0 1.10 (0.65-1.87) 1.01 (0.58-1.75) 1.29 (0.72-2.33) 0.4 1.12 (0.92-1.36) 
 Adjusted for smoking, BMI 1.0 0.92 (0.52-1.62) 0.71 (0.38-1.33) 0.83 (0.43-1.60) 0.7 0.96 (0.77-1.19) 
        
sTNF-R1 Quartile cut-offs [ng/ml] 0.75 - 1.13 1.14 - 1.31 1.32 - 1.58 1.59 - 2.95   
 No. cases / controls (total 390 / 390) 86 / 97 84 / 98 120 / 98 100 / 97   
 Crude d 1.0 0.97 (0.63-1.49) 1.41 (0.94-2.12) 1.23 (0.78-1.94) 0.2 1.39 (0.87-2.23) 
 Adjusted for smoking, BMI 1.0 0.84 (0.54-1.32) 1.18 (0.77-1.82) 0.95 (0.58-1.55) 0.9 1.10 (0.66-1.81) 
 Men, crude 1.0 0.72 (0.39-1.33) 0.81 (0.44-1.49) 0.71 (0.36-1.39) 0.4 0.67 (0.34-1.35) 
 Adjusted for smoking, BMI 1.0 0.71 (0.38-1.35) 0.79 (0.42-1.49) 0.64 (0.31-1.29) 0.3 0.63 (0.30-1.32) 
 Women, crude 1.0 1.23 (0.67-2.28) 2.25 (1.26-4.00) 1.97 (1.02-3.79) 0.02 2.74 (1.37-5.47) 
 Adjusted for smoking, BMI 1.0 1.03 (0.53-1.99) 1.75 (0.93-3.27) 1.47 (0.72-3.02) 0.2 2.05 (0.97-4.34) 
        
sTNF-R2 Quartile cut-offs [ng/ml] 0.83 - 1.95 1.96 - 2.31 2.32 - 2.68 2.69 - 4.82   
 No. cases / controls (total 414 / 414) 90 / 103 102 / 104 99 / 104 123 / 103   
 Crude d 1.0 1.17 (0.77-1.77) 1.18 (0.75-1.85) 1.52 (0.97-2.39) 0.07 1.55 (0.99-2.44) 
 Adjusted for smoking, BMI 1.0 1.15 (0.74-1.77) 1.08 (0.68-1.72) 1.42 (0.89-2.27) 0.2 1.40 (0.88-2.23) 
 Men, crude 1.0 1.06 (0.59-1.92) 0.98 (0.51-1.90) 1.20 (0.63-2.29) 0.6 1.24 (0.66-2.33) 
 Adjusted for smoking, BMI 1.0 1.02 (0.55-1.88) 0.92 (0.46-1.81) 1.27 (0.65-2.46) 0.4 1.35 (0.69-2.61) 
 Women, crude 1.0 1.28 (0.71-2.29) 1.40 (0.76-2.60) 1.92 (1.00-3.67) 0.05 1.95 (1.03-3.69) 
  Quartiles b  OR for doubling 
  1 2 3 4 Ρ trend c in concentration 
        
 Adjusted for smoking, BMI 1.0 1.22 (0.65-2.28) 1.17 (0.60-2.28) 1.72 (0.86-3.44) 0.1 1.60 (0.80-3.17) 
 
CI = confidence interval, No. = number. CRP, IL-6, and sTNF receptor concentrations on continuous scales were log2 transformed. Smaller number of subjects due to missing 
laboratory values. 
a Crude p-interaction over quartiles, for CRP = 0.03, IL-6 = 0.2, sTNF-R1 = 0.09, sTNF-R2 = 0.8. BMI and smoking adjusted p-interaction, for CRP = 0.03, IL-6 = 0.2, sTNF-
R1 = 0.1, sTNF-R2 = 0.9 
b Quartile cut points were based on the distribution of controls 
c P trend test was based on median values of each quartile 
d Logistic regression conditioned on matching factors (EPIC recruitment centre, sex, age at recruitment, date at entry in the cohort, time between blood sampling and last 
consumption of foods and drinks, hormone use). Adjusting variables in further model: smoking (former smokers adjusted for quitting smoking (< 10 or ≥ 10 years ago), 
current smokers adjusted for number of cigarettes (1-9, 10-19, or ≥ 20)), and BMI (continuous, [kg/m2]). 
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Figure 1: Crude relative risks [OR (95% CI)] of pancreatic cancer for a doubling in sTNF 
receptor concentrations, CRP, and IL-6, all and stratified by median BMI (26.2 for men, 24.6 
for women), diabetes, smoking status, and length of follow-up (≤ 2 vs. > 2yrs) 
 
 
Captain 
NOTE: Stratified analysis using unconditional logistic regression were adjusted for matching 
factors (EPIC recruitment centre, sex, age at blood collection, date of blood donation, time of 
blood donation, fasting status, and use of hormones). Ca / Co = number of cases / controls. 
Size of squares is proportional to number of participants in the respective subgroup; squares 
represent ORs, with error bars indicating 95% CIs. 
a P for interaction was based on the Wald statistics, adjusted for matching factors. 
b Median BMI for male controls was 26.20 kg/m2, for female controls 24.61 kg/m2. 
c Diabetics included subjects with self-reported diabetes status at baseline and subjects 
with glycated haemoglobin (HbA1c) levels ≥ 6.5% or both. 
d FUP = follow-up time [years], using conditional logistic regression. 
